Supplementary funding to support the extension of the EDCTP-funded ETEC Vaccine Efficacy study

Björn Sjöstrand先生（瑞典Scandinavian Biopharma Holding AB）主持的“支持延长edctp资助试验的补充资金”“非洲幼儿和儿童口服全细胞ETEC候选疫苗的实地研究：评估疗效并为关键的3期试验（ETEC疫苗疗效）设定参数”。由于Covid-19大流行的负面影响，研究推迟了。ETVAX®是一种ETEC全细胞灭活口服疫苗。ETVAX®通过防止ETEC细菌粘附在小肠细胞上并干扰ETEC毒素对这些细胞的影响而产生免疫力。科学家们认为ETVAX是临床上最先进的ETEC疫苗。这项1期研究的结果支持了ETVAX®在赞比亚成人和儿童中的安全性、耐受性和免疫原性。https://scandinavianbiopharma.se/studies/study-oev-124-phase-i-descending-age-study-in-a-lmic/和https://scandinavianbiopharma.se/studies/oev-128-phase-iib-study-in-children-6-18-months-in-a-lmic/”

"Supplementary funding to support the extension of the EDCTP-funded trial ""Field studies of an oral whole cell ETEC vaccine candidate in African toddlers and children: Assess efficacy and set parameters for pivotal Phase 3 trials (ETEC Vaccine Efficacy)"" held by Mr Björn Sjöstrand (Scandinavian Biopharma Holding AB, Sweden). Study delayed due to the negative impacts of the Covid-19 pandemic. ETVAX® is a killed whole-cell oral vaccine against ETEC. ETVAX® produces immunity by preventing ETEC bacteria from adhering to cells of the small intestine and interfering with the effects of ETEC toxins on these cells. Scientists recognize ETVAX as the most clinically advanced ETEC vaccine. The results of the Phase 1 study support the safety, tolerability, and immunogenicity of ETVAX® in adults and children in Zambia. https://scandinavianbiopharma.se/studies/study-oev-124-phase-i-descending-age-study-in-a-lmic/ and https://scandinavianbiopharma.se/studies/oev-128-phase-iib-study-in-children-6-18-months-in-a-lmic/"